NASDAQ:CNST - Constellation Pharmaceuticals Stock Price, News & Analysis

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Constellation Pharmaceuticals Inc (NASDAQ:CNST) released its earnings results on Wednesday, August, 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.80). View Constellation Pharmaceuticals' Earnings History.

Constellation Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Constellation Pharmaceuticals.

3 equities research analysts have issued 1 year price objectives for Constellation Pharmaceuticals' stock. Their predictions range from $17.00 to $18.00. On average, they expect Constellation Pharmaceuticals' stock price to reach $17.6667 in the next year. This suggests a possible upside of 164.5% from the stock's current price. View Analyst Price Targets for Constellation Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Constellation Pharmaceuticals.

Media headlines about CNST stock have been trending positive recently, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Constellation Pharmaceuticals earned a news impact score of 2.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for Constellation Pharmaceuticals.

Some companies that are related to Constellation Pharmaceuticals include TherapeuticsMD (TXMD), NextCure (NXTC), Endo International (ENDP), ZEALAND PHARMA/S (ZEAL), Catalyst Pharmaceuticals (CPRX), TG Therapeutics (TGTX), Vectura Group (VEGPF), Morphic (MORF), Stemline Therapeutics (STML), Synthorx (THOR), Achillion Pharmaceuticals (ACHN), Rocket Pharmaceuticals (RCKT), Karyopharm Therapeutics (KPTI), Kiniksa Pharmaceuticals (KNSA) and DiaMedica Therapeutics (DMCAF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Momo (MOMO), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), Novus Therapeutics (NVUS) and TherapeuticsMD (TXMD).

(CNST) raised $80 million in an IPO on Thursday, July 19th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

Constellation Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.18%), Vanguard Group Inc. (2.05%), Northern Trust Corp (0.57%), P.A.W. Capital Corp (0.46%), Alps Advisors Inc. (0.21%) and Bank of New York Mellon Corp (0.14%). Company insiders that own Constellation Pharmaceuticals stock include Alexandria Venture Investments, Anthony B Evnin and James E Flynn. View Institutional Ownership Trends for Constellation Pharmaceuticals.

CNST stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp. View Insider Buying and Selling for Constellation Pharmaceuticals.

CNST stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., P.A.W. Capital Corp, BlackRock Inc., Alps Advisors Inc., Jacobs Levy Equity Management Inc., Northern Trust Corp, Acadian Asset Management LLC and Wells Fargo & Company MN. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Alexandria Venture Investments, Anthony B Evnin and James E Flynn. View Insider Buying and Selling for Constellation Pharmaceuticals.

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CNST stock can currently be purchased for approximately $6.68.

Constellation Pharmaceuticals has a market capitalization of $172.48 million. The company earns $-59,920,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.View Additional Information About Constellation Pharmaceuticals.

The official website for Constellation Pharmaceuticals is http://www.constellationpharma.com/.

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]